Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building

Ultragenyx Pharmaceutical bought two precedence overview vouchers, every from an FDA approval of a gene remedy. Each therapies got here from enterprise offers and proceeds from the voucher gross sales put Ultragenyx in a greater monetary place to pursue yet one more deal for a uncommon illness asset.

The put up Ultragenyx Uncommon Illness Voucher Gross sales Safe $413M for Extra Potential Pipeline Constructing appeared first on MedCity Information.

Source link